Brief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Yesterday 13:45
BRIEF-Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer Oct 21 (Reuters) - Akeso Inc 9926.HK:
AKESO ANNOUNCES SUMMIT THERAPEUTICS AND ECOG-ACRIN CANCER RESEARCH GROUP ENTER INTO PHASE II/III CLINICAL TRIAL COLLABORATION TO EVALUATE IVONESCIMAB IN FIRST-LINE BILIARY TRACT CANCER
AKESO - CLINICAL TRIAL SITE ACTIVATIONS IN U.S. EXPECTED TO BEGIN Q4 2026
Source text: ID:nPn7FcqhJa
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)